Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 61

1.

A novel deep targeted sequencing method for minimal residual disease monitoring in acute myeloid leukemia.

Onecha E, Linares M, Rapado I, Ruiz-Heredia Y, Martinez-Sanchez P, Cedena T, Pratcorona M, Oteyza JP, Herrera P, Barragan E, Montesinos P, Vela JAG, Magro E, Anguita E, Figuera A, Riaza R, Martinez-Barranco P, Sanchez-Vega B, Nomdedeu J, Gallardo M, Martinez-Lopez J, Ayala R.

Haematologica. 2019 Feb;104(2):288-296. doi: 10.3324/haematol.2018.194712. Epub 2018 Aug 9.

2.

Lenalidomide in Pretreated Mantle Cell Lymphoma Patients: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice (the Lenamant Study).

Stefoni V, Pellegrini C, Broccoli A, Baldini L, Tani M, Cencini E, Figuera A, Ansuinelli M, Bernocco E, Cantonetti M, Cox MC, Ballerini F, Rusconi C, Visco C, Arcaini L, Fama A, Marasca R, Volpetti S, Castellino A, Califano C, Cavaliere M, Gini G, Liberati AM, Musuraca G, Lucania A, Ricciuti G, Argnani L, Zinzani PL.

Oncologist. 2018 Sep;23(9):1033-1038. doi: 10.1634/theoncologist.2017-0597. Epub 2018 Apr 19.

3.

Busulfan-based reduced intensity conditioning regimens for haploidentical transplantation in relapsed/refractory Hodgkin lymphoma: Spanish multicenter experience.

Gayoso J, Balsalobre P, Pascual MJ, Castilla-Llorente C, López-Corral L, Kwon M, Serrano D, Piñana JL, Herrera P, Ferrá C, Pascual C, Heras I, Montesinos P, Zabalza A, Bento L, Figuera A, Buño I, Díez-Martín JL.

Bone Marrow Transplant. 2016 Oct;51(10):1307-1312. doi: 10.1038/bmt.2016.115. Epub 2016 May 9.

PMID:
27159177
4.

Romidepsin in relapsed/refractory T-cell lymphomas: Italian experience and results of a named patient program.

Zinzani PL, Pellegrini C, Cerciello G, Monaco F, Volpetti S, Peli A, Angelucci E, Corradini P, Cox MC, Guarini A, Musso M, Bresciani P, Amato G, Billio A, Caparrotti G, Figuera A, Nassi L, Gaudio F, Grossi A, Onida F, Merli M, Rigacci L, Argnani L.

Leuk Lymphoma. 2016 Oct;57(10):2370-4. doi: 10.3109/10428194.2015.1137292. Epub 2016 Feb 17.

PMID:
26732313
5.

The impact of climate change on the geographical distribution of two vectors of Chagas disease: implications for the force of infection.

Medone P, Ceccarelli S, Parham PE, Figuera A, Rabinovich JE.

Philos Trans R Soc Lond B Biol Sci. 2015 Apr 5;370(1665). pii: 20130560. doi: 10.1098/rstb.2013.0560.

6.

Circulating myeloid-derived suppressor cells correlate with clinical outcome in Hodgkin Lymphoma patients treated up-front with a risk-adapted strategy.

Romano A, Parrinello NL, Vetro C, Forte S, Chiarenza A, Figuera A, Motta G, Palumbo GA, Ippolito M, Consoli U, Di Raimondo F.

Br J Haematol. 2015 Mar;168(5):689-700. doi: 10.1111/bjh.13198. Epub 2014 Nov 7.

PMID:
25376846
7.

Endoscopic features of gastro-intestinal lymphomas: from diagnosis to follow-up.

Vetro C, Romano A, Amico I, Conticello C, Motta G, Figuera A, Chiarenza A, Di Raimondo C, Giulietti G, Bonanno G, Palumbo GA, Di Raimondo F.

World J Gastroenterol. 2014 Sep 28;20(36):12993-3005. doi: 10.3748/wjg.v20.i36.12993. Review.

8.

Impact of the International Prognostic Scoring System cytogenetic risk groups on the outcome of patients with primary myelodysplastic syndromes undergoing allogeneic stem cell transplantation from human leukocyte antigen-identical siblings: a retrospective analysis of the European Society for Blood and Marrow Transplantation-Chronic Malignancies Working Party.

Onida F, Brand R, van Biezen A, Schaap M, von dem Borne PA, Maertens J, Beelen DW, Carreras E, Alessandrino EP, Volin L, Kuball JH, Figuera A, Sierra J, Finke J, Kröger N, de Witte T; MDS subcommittee of the EBMT-CMWP.

Haematologica. 2014 Oct;99(10):1582-90. doi: 10.3324/haematol.2014.106880. Epub 2014 Aug 1.

9.

Incidence, risk factors, and outcome of bacteremia following autologous hematopoietic stem cell transplantation in 720 adult patients.

Piñana JL, Montesinos P, Martino R, Vazquez L, Rovira M, López J, Batlle M, Figuera Á, Barba P, Lahuerta JJ, Debén G, Perez-Lopez C, García R, Rosique P, Lavilla E, Gascón A, Martínez-Cuadrón D, Sanz MÁ.

Ann Hematol. 2014 Feb;93(2):299-307. doi: 10.1007/s00277-013-1872-4. Epub 2013 Sep 1.

PMID:
23995612
10.

Transforming and tumorigenic activity of JAK2 by fusion to BCR: molecular mechanisms of action of a novel BCR-JAK2 tyrosine-kinase.

Cuesta-Domínguez Á, Ortega M, Ormazábal C, Santos-Roncero M, Galán-Díez M, Steegmann JL, Figuera Á, Arranz E, Vizmanos JL, Bueren JA, Río P, Fernández-Ruiz E.

PLoS One. 2012;7(2):e32451. doi: 10.1371/journal.pone.0032451. Epub 2012 Feb 27.

11.

Origin, functional role, and clinical impact of Fanconi anemia FANCA mutations.

Castella M, Pujol R, Callén E, Trujillo JP, Casado JA, Gille H, Lach FP, Auerbach AD, Schindler D, Benítez J, Porto B, Ferro T, Muñoz A, Sevilla J, Madero L, Cela E, Beléndez C, de Heredia CD, Olivé T, de Toledo JS, Badell I, Torrent M, Estella J, Dasí A, Rodríguez-Villa A, Gómez P, Barbot J, Tapia M, Molinés A, Figuera A, Bueren JA, Surrallés J.

Blood. 2011 Apr 7;117(14):3759-69. doi: 10.1182/blood-2010-08-299917. Epub 2011 Jan 27.

12.

Chromosome fragility in patients with Fanconi anaemia: diagnostic implications and clinical impact.

Castella M, Pujol R, Callén E, Ramírez MJ, Casado JA, Talavera M, Ferro T, Muñoz A, Sevilla J, Madero L, Cela E, Beléndez C, de Heredia CD, Olivé T, de Toledo JS, Badell I, Estella J, Dasí Á, Rodríguez-Villa A, Gómez P, Tapia M, Molinés A, Figuera Á, Bueren JA, Surrallés J.

J Med Genet. 2011 Apr;48(4):242-50. doi: 10.1136/jmg.2010.084210. Epub 2011 Jan 7.

PMID:
21217111
13.

Stage IV cutaneous acute graft-versus-host disease. Clinical and histological study of 15 cases.

Goiriz R, Peñas P, Pérez-Gala S, Delgado-Jiménez Y, Aragüés M, García-Diez A, Fraga J, Figuera A, Fernández-Herrera J.

J Eur Acad Dermatol Venereol. 2009 Dec;23(12):1398-404. doi: 10.1111/j.1468-3083.2009.03326.x. Epub 2009 Jun 8.

PMID:
19522707
14.

Acute promyelocytic leukemia during pregnancy: report of 3 cases.

Consoli U, Figuera A, Milone G, Meli CR, Guido G, Indelicato F, Moschetti G, Leotta S, Tornello A, Poidomani M, Murgano P, Pinto V, Giustolisi R.

Int J Hematol. 2004 Jan;79(1):31-6. Review.

PMID:
14979475
15.

Quality of life and psychological well-being in Spanish long-term survivors of Hodgkin's disease: results of a controlled pilot study.

Gil-Fernández J, Ramos C, Tamayo T, Tomás F, Figuera A, Arranz R, Martínez-Chamorro C, Fernández-Rañada M.

Ann Hematol. 2003 Jan;82(1):14-8. Epub 2002 Dec 19.

PMID:
12574958
16.

Allogeneic hematopoietic stem cell transplantation in patients 50 years of age and older.

de la Cámara R, Alonso A, Steegmann JL, Arranz R, Granados E, Rodríguez-Macías G, Sanz-Rodríguez C, de Soria VG, Figuera A, Fernández-Rañada JM.

Haematologica. 2002 Sep;87(9):965-72.

17.

Clinafloxacin monotherapy (CI-960) versus ceftazidime plus amikacin for empirical treatment of febrile neutropenic cancer patients.

Glauser MP, Brennscheidt U, Cornely O, Grigg A, Figuera A, Keyserling C, Trostmann U, Welling L, Tack K.

Clin Microbiol Infect. 2002 Jan;8(1):14-25.

18.

[Comparative study of piperacillin/tazobactam versus imipenem/cilastatin in febrile neutropenia (1994-1996)].

Figuera A, Rivero N, Pajuelo F, Font P, Leyra F, de La Cámara R, Arranz R, María Fernández Rañada J.

Med Clin (Barc). 2001 May 5;116(16):610-1. Spanish.

PMID:
11412645
19.

Plasma endothelin-1 levels after stem cell transplantation.

Tomis JF, Sanz-Rodriguez C, de Soria VG, Font P, Sánchez S, Gruss E, Figuera A, Fernández-Rañada JM.

Bone Marrow Transplant. 2000 Dec;26(11):1199-204.

20.

Long-term liver dysfunction after allogeneic bone marrow transplantation: clinical features and course in 61 patients.

Tomás JF, Pinilla I, García-Buey ML, García A, Figuera A, Gómez-García de Soria VGG, Moreno R, Fernández-Rañada JM.

Bone Marrow Transplant. 2000 Sep;26(6):649-55.

21.

Hematopoietic cell transplantation in acute lymphoblastic leukemia: better long term event-free survival with conditioning regimens containing total body irradiation.

Granados E, de La Cámara R, Madero L, Díaz MA, Martín-Regueira P, Steegmann JL, Arranz R, Figuera A, Fernández-Rañada JM.

Haematologica. 2000 Oct;85(10):1060-7.

22.

[Treatment of leukemia relapsed after allogenic bone marrow transplantation with donor lymphocyte infusion: report of 11 cases].

Sanz Rodríguez C, Steegmann JL, Granda A, de la Cámara R, Figuera A, Arranz R, Gómez-García de Soria V, Alegre A, Fernández-Rañada JM.

Sangre (Barc). 1999 Dec;44(6):456-63. Spanish.

PMID:
10822760
23.

Interferon alpha for chronic myeloid leukemia relapsing after allogeneic bone marrow transplantation.

Steegmann JL, Casado LF, Tomás JF, Sanz-Rodríguez C, Granados E, de la Cámara R, Alegre A, Vázquez L, Ferro MT, Figuera A, Arranz R, Fernández-Rañada JM.

Bone Marrow Transplant. 1999 Mar;23(5):483-8.

24.

Allogeneic transplantation of selected CD34+ cells from peripheral blood: experience of 62 cases using immunoadsorption or immunomagnetic technique. Spanish Group of Allo-PBT.

Urbano-Ispizua A, Solano C, Brunet S, de la Rubia J, Odriozola J, Zuazu J, Figuera A, Caballero D, Martínez C, García J, Sanz G, Torrabadella M, Alegre A, Pérez-Oteiza J, Jurado M, Oyonarte S, Sierra J, García-Conde J, Rozman C.

Bone Marrow Transplant. 1998 Sep;22(6):519-25.

25.

Allogeneic transplantation of purified CD34+ cells from peripheral blood: Spanish experience of 62 cases. Spanish Group of allo-PBT.

Urbano-Ispizua A, Solano C, Brunet S, de la Rubia J, Odriozola J, Zuazu J, Figuera A, Caballero D, Martínez C, García J, Sanz G, Torrabadella M, Alegre A, Pérez-Oteiza J, Jurado M, Oyonarte S, Sierra J, García-Conde J, Rozman C.

Bone Marrow Transplant. 1998 Jun;21 Suppl 3:S71-4.

PMID:
9712500
26.

Absence of influence of prior treatment with interferon on the outcome of allogeneic bone marrow transplantation for chronic myeloid leukemia.

Tomás JF, López-Lorenzo JL, Requena MJ, Aguilar R, Steegmann JL, Cámara R, Alegre A, Arranz R, Figuera A, Fernández-Rañada JM.

Bone Marrow Transplant. 1998 Jul;22(1):47-51.

27.

Autologous stem cell transplantation (ASCT) for poor prognostic Hodgkin's disease (HD): comparative results with two CBV regimens and importance of disease status at transplant.

Arranz R, Tomás JF, Gil-Fernández JJ, Martínez-Chamorro C, Granados E, Alegre A, Figuera A, Vázquez L, Cámara R, Fernández-Rañada JM.

Bone Marrow Transplant. 1998 Apr;21(8):779-86.

28.

Unexpected late graft failure 9 months after HLA-identical bone marrow transplant (BMT) for chronic myeloid leukemia (CML): treatment with a second BMT.

Gil-Fernández JJ, Arranz R, Cámara R, Alegre A, Figuera A, Fernández-Rañada JM.

Haematologica. 1998 Mar;83(3):285-7.

29.

Meropenem versus ceftazidime plus amikacin in the treatment of febrile episodes in neutropenic patients: a randomized study.

de la Cámara R, Figuera A, Sureda A, Hermida G, Verge G, Olalla I, Fernández Rañada JM, Domingo Albos A.

Haematologica. 1997 Nov-Dec;82(6):668-75.

30.

High incidence of chronic graft versus host disease after allogeneic peripheral blood progenitor cell transplantation. The Spanish Group of Allo-PBPCT.

Urbano-Ispizua A, García-Conde J, Brunet S, Hernández F, Sanz G, Petit J, Bargay J, Figuera A, Rovira M, Solano C, Ojeda E, de la Rubia J, Rozman C.

Haematologica. 1997 Nov-Dec;82(6):683-9.

31.

Chemotherapy-induced eccrine squamous syringometaplasia. A distinctive eruption in patients receiving hematopoietic progenitor cells.

Valks R, Fraga J, Porras-Luque J, Figuera A, Garcia-Diéz A, Fernändez-Herrera J.

Arch Dermatol. 1997 Jul;133(7):873-8.

PMID:
9236526
32.

[Access to bone marrow transplantation in acute myeloblastic leukemia. Study of 52 patients treated in a single center].

Tomás JF, Calvo JM, Gómez-García de Soria V, Pinilla I, Figuera A, Fernández-Rañada JM.

Med Clin (Barc). 1997 May 31;109(1):12-5. Spanish.

PMID:
9303971
33.

[Allogeneic transplant of CD34+ peripheral blood cells from HLA-identical donors: Spanish experience of 40 cases. Allo-Peripheral Blood Transplantation Group].

Urbano-Ispizua A, Solano C, Brunet S, de la Rubia J, Odriozola J, Zuazu J, Figuera A, Caballero D, Martínez C, García J, Sanz G, Torrabadella M, Alegre A, Pérez-Oteyza J, Sierra J, García-Conde J, Rozman C.

Sangre (Barc). 1997 Apr;42 Suppl 1:44-5. Spanish. No abstract available.

PMID:
9381302
34.

[Allogenic transplant of non-manipulated hematopoietic progenitor peripheral blood cells. Spanish experience of 79 cases. Allo-Peripheral Blood Transplantation Group].

Brunet S, Urbano-Ispizua A, Solano C, Ojeda E, Caballero D, Torrabadella M, de la Rubia J, Pérez-Oteiza J, Moraleda J, Espigado I, de la Serna J, Petit J, Bargay J, Mataix R, Vivancos P, Figuera A, Sierra J, Domingo-Albós A, Hernández F, García Conde J, Rozman C.

Sangre (Barc). 1997 Apr;42 Suppl 1:42-3. Spanish. No abstract available.

PMID:
9381301
35.

[Bone marrow autotransplantation in acute myeloblastic leukemia in its first complete remission. The clinical results in 41 patients].

Tomás JF, Gómez-García de Soria V, Pinilla I, Lamana M, Figuera A, Arranz R, Cámara R, Fernández-Villalta MJ, Alegre A, Fernández-Rañada JM.

Med Clin (Barc). 1997 Feb 15;108(6):201-6. Spanish.

PMID:
9102484
36.

Clinical results of a stringent policy on prophylactic platelet transfusion: non-randomized comparative analysis in 190 bone marrow transplant patients from a single institution.

Gil-Fernández JJ, Alegre A, Fernández-Villalta MJ, Pinilla I, Gómez García V, Martinez C, Tomás JF, Arranz R, Figuera A, Cámara R, Fernández-Rañada JM.

Bone Marrow Transplant. 1996 Nov;18(5):931-5.

PMID:
8932847
37.

[Imipenem combined with teicoplanin or vancomycin in the initial empirical treatment of febrile neutropenia. Analysis of the primary response and of a global sequential strategy in 126 episodes].

Figuera A, Tomás JF, Hernández L, Jiménez ML, Peñarrubia MJ, del Rey MC, Arranz R, Cámara R, López-Lorenzo JL, Fernández-Rañada JM.

Rev Clin Esp. 1996 Aug;196(8):515-22. Spanish.

PMID:
8984537
38.

Autologous or allogeneic bone marrow transplantation for acute myeloblastic leukemia in second complete remission. Importance of duration of first complete remission in final outcome.

Tomás F, Gómez-García de Soria V, López-Lorenzo JL, Arranz R, Figuera A, Cámara R, Alegre A, Fernández-Rañada JM.

Bone Marrow Transplant. 1996 Jun;17(6):979-84.

PMID:
8807103
39.

Orthotopic liver transplantation for acute grade IV hepatic graft-versus-host disease following bone marrow transplantation.

Figuera A, Tomás JF, Otero MJ, Moreno E, García I, Fernández-Rañada JM.

Am J Hematol. 1996 May;52(1):68-9. No abstract available.

40.

[Allogeneic bone marrow transplantation in chronic myeloid leukemia. The clinical results and risk factors in 70 patients].

Tomás JF, Peñarrubia MJ, García JA, Figuera A, Gómez-García de Soria V, Steegmann JL, Arranz R, Cámara R, Gabriel R, Vázquez L, et al.

Med Clin (Barc). 1995 Nov 11;105(16):605-11. Spanish.

PMID:
8523939
41.

Busulfan and melphalan as conditioning regimen for autologous peripheral blood stem cell transplantation in multiple myeloma.

Alegre A, Lamana M, Arranz R, Fernández-Villalta MJ, Tomás JF, Figuera A, Cámara R, Steegman JL, Casado F, Requena MJ, et al.

Br J Haematol. 1995 Oct;91(2):380-6.

PMID:
8547079
42.

Acute renal failure in patients following bone marrow transplantation: prevalence, risk factors and outcome.

Gruss E, Bernis C, Tomas JF, Garcia-Canton C, Figuera A, Motellón JL, Paraiso V, Traver JA, Fernandez-Rañada JM.

Am J Nephrol. 1995;15(6):473-9.

PMID:
8546168
43.

[Early bacterial infections in 103 patients treated with bone marrow transplantation].

Tomás JF, Hernández LM, Peñarrubia MJ, Figuera A, Jiménez ML, Cámara R, Arranz R, López JL, Cruz J, Fernández-Rañada JM.

Sangre (Barc). 1994 Jun;39(3):191-6. Review. Spanish.

PMID:
7940049
44.

Clinical results in 50 multiply transfused patients with severe aplastic anemia treated with bone marrow transplantation or immunosuppressive therapy.

Arranz R, Otero MJ, Ramos R, Steegmann JL, Lamana ML, Tomás JF, de la Cámara R, Figuera A, Vázquez L, Fernádez-Rañada JM.

Bone Marrow Transplant. 1994 Apr;13(4):383-7.

PMID:
8019461
45.

Fractionated TBI and methotrexate-cyclosporin do not seem to increase relapses in BMT for first chronic phase CML patients: results of a single centre study.

López J, Vázquez L, Serrano F, Kassack JJ, Figuera A, Steegmann JL, Cámara R, Lamana M, Ferro T, Fernández-Villalta MJ, et al.

Bone Marrow Transplant. 1992 Sep;10(3):235-9.

PMID:
1422477
46.

Allogeneic bone marrow transplantation for high risk acute lymphoblastic leukemia. Results from a single institution.

De la Cámara R, Figuera A, Steegmann JL, Tomás JF, López J, Somolinos N, Arranz R, Vázquez L, Fernández Rañada JM.

Bone Marrow Transplant. 1992 Jun;9(6):433-8.

PMID:
1628127
47.

Unexpectedly high toxicity of MACOP-B in young patients with low grade lymphoma.

Arranz R, Pérez G, Steegmann JL, Cámara R, Tomás JF, Figuera A, Vazquez L, Fernández-Rañada JM.

Am J Hematol. 1991 Sep;38(1):75-6.

PMID:
1716853
48.

High dose busulfan and seizures.

De La Camara R, Tomas JF, Figuera A, Berberana M, Fernandez-Rañada JM.

Bone Marrow Transplant. 1991 May;7(5):363-4.

PMID:
2070145
49.

Relation between the increase of circulating CD3+ CD57+ lymphocytes and T cell dysfunction in recipients of bone marrow transplantation.

Izquierdo M, Balboa MA, Fernández-Rañada JM, Figuera A, Torres A, Iriondo A, López-Botet M.

Clin Exp Immunol. 1990 Oct;82(1):145-50.

50.

[Treatment of severe aplastic anemia with bone marrow transplants or with antithymocyte globulin. Evaluation of 27 patients].

Arranz R, Steegmann JL, Fernández-Garesse D, Figuera A, Vázquez L, Fernández-Rañada JM.

Rev Clin Esp. 1989 Feb;184(3):121-4. Spanish.

PMID:
2655043

Supplemental Content

Loading ...
Support Center